PROCESS ANALYTICAL TECHNOLOGY – A REVIEW By Mr. Akash Mali DEPARTMENT OF PHARMACEUTICS, G.I.P.E.R., LIMB, SATARA. 1.

Slides:



Advertisements
Similar presentations
FDA/Industry Statistics Workshop Washington D.C. September 27-29, 2006
Advertisements

1 Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS,
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
Pharmtech Contract Services Offered by the Division of Pharmaceutical Technology.
Process Analytical Technologies Subcommittee Product and Process Development: An Industry Perspective David Rudd PhD Process Technology GlaxoSmithKline.
Manufacturing Subcommittee of the Advisory Committee for Pharmaceutical Science July 20-21, 2004 Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.
By: Muhammad Naeem Quality Assurance and Regulatory Manager
1 MEASURING THE EFFECTIVENESS OF THE NATION’S FOODSERVICE AND RETAIL FOOD PROTECTION SYSTEM.
PAT Validation Working Group Process and Analytical Validation Working Group Arthur H. Kibbe, Ph.D. Chair June 13, 2002.
ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.
FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.
Huzairy Hassan School of Bioprocess Engineering UniMAP.
Learnings from Pre-approval Joint Inspection of a GSK QbD Product with US-FDA & EMA and the application of Continuous Verification 17 May 2011, Beijing,
Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.
Figure 3: Process fingerprint monitoring of a bio- reactor Biopharm production methods need effective real-time monitoring and control to guarantee a low-cost,
Xcellerex … speeding medicines to people … PAT for Biologics Ensuring Quality of Biologically Produced Drugs FDA Advisory Committee on Pharmaceutical Sciences.
Application of the principles of QbD in vaccines production Andrea Pranti.
COMPANY PRESENTATION TO: MONTH XX, Agenda Who we are Our experience Benefits of measuring with light The Prozess Technologie solution Identify YOUR.
FDA Regulatory Perspective on Continuous Manufacturing
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
Applications and benefits of PAT Steve Hammond Global Manufacturing Services Process Analytical Support Group Sandwich, UK.
Slide 1 May 2008 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008 QUALITY BY DESIGN.
Quality by Design Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants.
D. Christopher Watts, Ph.D. Office of Pharmaceutical Science, CDER, FDA Science Seminar Series for the Office of Commissioner April 9, 2004 Process Analytical.
1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.
Office of Research and Development Photo image area measures 1.5” H x 7” and can be masked by a collage strip of one, two or three images. The photo image.
Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.
Shelf Life Extension Program (SLEP)
FDA Regulation of Drug Quality: New Challenges Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research, Food and Drug Administration April.
1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.
FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.
Quality by Design (QbD) Myth : An expensive development tool ! Fact : A tool that makes product development and commercial scale manufacturing simple !
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
 Siemens Nederland N.V FDA13April Presented by Troy Logan at the Advisory Committee for Pharmaceutical Science meeting on April 13, 2004.
1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.
1 An Update on ICH Guideline Q8 – Pharmaceutical Development FDA Advisory Committee for Pharmaceutical Science: 5 Oct 2006 Dr John C Berridge Senior Regulatory.
10/11/ ENGINEERING RESEARCH CENTER FOR S TRUCTURED O RGANIC P ARTICULATE S YSTEMS RUTGERS UNIVERSITY PURDUE UNIVERSITY NEW JERSEY INSTITUTE OF TECHNOLOGY.
Small molecules Liquids – Solvent composition – Reactions – HME Dry Powder – Blending – Dry Granulation – Dry milling Wet solids – API Crystallization.
Molecule-to-Market-Place Quality
HACCP Prepared By: Mrs. F. Malcolm-Hanson Date: 29 th November,2013 Group: 2 nd Year (Nutrition) Week: 12.
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
10:00 A.M. – Noon 7 June 2004 ICH Quality Plenary Meeting.
FDA PROCESS ANALYTICAL TECHNOLOGY SUB COMMITTEE MEETING 25 TH FEBRUARY 2002 PERSPECTIVE ON PROCESS AND ANALYTICAL VALIDATION Robert S Chisholm.
1 Office of Pharmaceutical Science on Jon Clark FDA/CDER/OPS Associate Director for Policy Development.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
Pharmaceutical Manufacturing Subcommittee of the ACPS Ajaz S. Hussain, Ph.D. ACPS Meeting October 22, 2002.
1 PAT Subcommittee Closing Report 12 March 2003 Tom Layloff Acting Chair.
Process Analytical Technologies (PATs), Applications and Benefits Working Group.
CDER / Office of Compliance ACPS October 5, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA.
FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Closing Remarks Ajaz S. Hussain, Ph.D. Deputy.
FDA PAT Sub-Committee of Advisory Committee for Pharmaceutical Sciences June 12-13, 2002; Gaithersburg, MD Regulatory Challenges: Post-Approval PAT Applications.
Use of Risk-based Approach for Regulating CMC Changes to Approved Applications FDA Public Meeting February 7, 2007.
FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.
© G.K.Raju, Ph.D. Manufacturing Science May 21st 2003 MANUFACTURING SCIENCE: The Means To GMPs In the 21 st Century.. G.K.Raju, Ph.D.
开发报批美国 FDA 的仿制药 与相关问题探讨 上海复星普适医药科技有限公司何平. 内容提要 开发仿制药的重要性和机遇 开发仿制药的重要性和机遇 开发仿制药的挑战 开发仿制药的挑战 申报仿制药的分类 申报仿制药的分类 仿制药研发团队 仿制药研发团队 仿制药的研发过程 仿制药的研发过程 QbD 在制剂开发中怎么体现.
QbD Technologies: Workshop for Risks Management Incorporating Risk Management for Technology Transfer.
Product & Process Working Group February 26, 2002.
GMP -Regulatory Perspective Sukanti Borkar Abbott India Ltd.
Michael Kopcha, Ph.D., R.Ph. Director Office of Pharmaceutical Quality
An Update on ICH Guideline – Pharmaceutical Development
Project Management (x470)
,Branko Vranic1, Nada Tarek2 ,V. Frost 3, G. Betz1
Quality System.
Dr Dehghan M. H Professor in Pharmaceutics,
QUALITY BY DESIGN Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008.
Michael I. Sadowski, Chris Grant, Tim S. Fell  Trends in Biotechnology 
26th Meeting of the Wiesbaden Group on Business Registers
Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.
Quality by Design.
GL 51 – Statistical evaluation of stability data
Presentation transcript:

PROCESS ANALYTICAL TECHNOLOGY – A REVIEW By Mr. Akash Mali DEPARTMENT OF PHARMACEUTICS, G.I.P.E.R., LIMB, SATARA. 1

Sr.No.Content 1.Abstract 2.Introduction 3.Background 4.PAT Goals 5.How PAT Works- An Instant 6.PAT Tools 7.Strategy For Implementation 8.Benefits 9.Applications 10. PAT applications in Pharmaceutical & Chemical Industry 11.Conclusion 12.References INDEX 2

 Designing, analyzing, and controlling manufacturing.  Timely measurements.  Critical quality and performance attributes.  Raw and in-process materials.  and processes. 3

Figure 1: Major area covered by PAT 4

The conventional approach has been successful in providing quality pharmaceuticals to the public. The problem with this type of approach is that if at final testing product fails to pass the quality specifications. So, The Food and Drug Administration (FDA) are inviting discussions throughout the pharmaceutical industry concerning a new mode of operation, which will address these concerns. This mode of operation is known as Process Analytical Technology (PAT). 5

The goal of PAT is to understand and control the manufacturing process, which is consistent with our current drug quality system; quality cannot be tested into products; it should be build in product by design. 6

The goals are intended to ensure that: The most up-to-date concepts of risk management and quality systems approaches are incorporated into the manufacture of Pharmaceuticals while maintaining product quality. Manufacturers are encouraged to use the latest scientific advances in Pharmaceutical manufacturing and technology. The agency's submission review and inspection programs operate in a coordinated and synergistic manner. Regulations and manufacturing standards are applied consistently by the Agency and the manufacturer. Management of the Agency's Risk-Based Approach encourages innovation in the pharmaceutical manufacturing sector. 7

There are many current and new tools available that enable scientific, risk managed pharmaceutical development, manufacture, and quality assurance. In the PAT framework, these tools can be categorized according to following:  Multivariate data acquisition and analysis tools  Modern process analyzers or process analytical chemistry tools  Process and endpoint monitoring and controlling tools  Continuous improvement and knowledge improvement 8

There are different development strategies that can be used to identify optimal formulation and process conditions for physical, chemical, or biological perspective of pharmaceutical products and processes. The knowledge acquired in these development programs are the foundation for product and process design. Some manufacturers use multivariate mathematical approaches, such as statistical design of experiments, response surface methodologies, process simulation, and pattern recognition tools, in conjunction with knowledge management systems. 9

Off line in a laboratory At line in the production area, during production close to the manufacturing process Online where measurement system is connected to the process via a diverted sample stream ;the sample may be return to the process stream after measurement In line where process stream may be disturbed (e.g. probe insertion),and measurement done in real time Noninvasive,when the sensor is not in contact with the material (e.g., Raman spectroscopy through a window)in the processor, the process stream is not disturbed 10

Following steps can be included for design and optimization of drug formulations and manufacturing process within the PAT framework:  Identify and measure critical material and process attributes relating to product quality  Design a process measurement system to allow real time or near real time (e.g., on-, in-, or at- line )monitoring of all critical attributes  Design process controls that provide adjustments to ensure control of all critical attributes.  Develop mathematical relationship between product quality attributes and  Measurement of critical material and process attributes. 11

Continuous learning through data collection and analysis over the life cycle of a product is important. Data can contribute to justifying proposal for post approval changes including introduction of new technologies. Approaches and information technology system that support knowledge acquisition from such databases are valuable for the manufactures and can also facilitate scientific communication with the regulatory agency. 12

21 st Century Quality Approach Add PAT Measure raw materials attributes Add pat Measure critical quality Raw materials Process Product Adjust CPP’s in Response to RMA’s Process Variables Adjust CPP’s in response to CQA’S PAT Fig 3: 21 st Century Quality Approach 13

14

 BioPAT BioPAT as process analytical technologies applied throughout development, scale-up and commercial scale bioprocess-based production of drug substances (including manufacturing of intermediates, APIs and the final drug products. In this report, we will focus on what PAT means in practice for the biotechnological manufacture of Pharmaceuticals. 15

16

17

ApplicationProcess AnalyzerObservation Analysis of organic content of waste water NMR Spectroscopy Less time & cost effective method Raw material identification and quality control Near infrared (NIR) Spectroscopy Fast &cost effective method Simultaneous monitoring of solute concentration and polymorphic state of crystal Raman Spectroscopy & Attenuated total reflectance(ATR) and FTIR Know how the rate of addition of reactant affects the Polymorphic state of crystal Catalysis reaction involving conversion of acetone to Methyl isobutyl ketone (MIBK) In- line NIRAffects Productivity, selectivity, and yield of MIBK 18

PATProcess Attribute analyzed On/in/o ff-line NIR spectroscopy- Transmission Compression Quantification of active ingredient Off-line Temperature sensor & increase Granulation Granulation end point In line NIR spectroscopy- Reflectance Raw materialIdentificationOff-line NIR spectroscopy- Reflectance Packing lineIdentificationon -line NIR spectroscopy- Reflectance granulation Wet granulation end point On- line 19

NIR spectroscopy- Reflectance Compression – tablets & capsules Content uniformity & assay Off-line NIR spectroscopy- Reflectance PowderMoister contentOff-line Image probe (CCD camera & high energy XE lighting system) High shear granulation Partical size & shape In line FT-IR with ATR probe Pharmaceutical salt formation process End point monitoring In line Raman spectroscopyCompressionAnalysis of API in tablets Off line 20

21